- Home
- STTK vs ONT Comparison
STTK vs ONT Comparison
Compare STTK & ONT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STTK | ONT |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.3M | 600.3M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STTK | ONT |
|---|---|---|
| Price | $7.36 | $19.65 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 559.5K |
| Earning Date | 05-01-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $15.95 |
| 52 Week High | $8.33 | $22.50 |
Technical Indicators
Market Signals| Indicator | STTK | ONT |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 56.46 |
| Support Level | $5.87 | $18.46 |
| Resistance Level | $7.64 | $22.10 |
| Average True Range (ATR) | 0.62 | 1.12 |
| MACD | 0.00 | -0.35 |
| Stochastic Oscillator | 71.63 | 26.49 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.